1. Scrip
  2. >>COVID-19

Inovio To Streamline COVID-19 Vaccine Program Under New CEO

 
• By Alaric DeArment

The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.

Inovio is shifting gears in its product development strategy as the company appoints a new CEO • Source: Shutterstock

Inovio Pharmaceuticals, Inc. announced it is changing course with its COVID-19 vaccine in an effort to develop it as a booster shot as the pandemic transitions to an endemic, while also announcing a setback for its lead clinical program for cervical dysplasia and that a new CEO is taking over from previous CEO J. Joseph Kim.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.